These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 12176857)
1. Cancer vaccines and immunotherapy. Dermime S; Armstrong A; Hawkins RE; Stern PL Br Med Bull; 2002; 62():149-62. PubMed ID: 12176857 [TBL] [Abstract][Full Text] [Related]
2. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. Jäger D; Jäger E; Knuth A J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070 [TBL] [Abstract][Full Text] [Related]
3. DNA vaccine for cancer immunotherapy. Yang B; Jeang J; Yang A; Wu TC; Hung CF Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927 [TBL] [Abstract][Full Text] [Related]
4. Specific immunotherapy of cancer in elderly patients. Matzku S; Zöller M Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells as vectors for immunotherapy of cancer. Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163 [TBL] [Abstract][Full Text] [Related]
6. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391 [TBL] [Abstract][Full Text] [Related]
7. [Identification of cancer antigens of relevance for specific cancer immunotherapy]. van den Eynde B Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273 [TBL] [Abstract][Full Text] [Related]
8. Immune based therapies in cancer. Krüger C; Greten TF; Korangy F Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098 [TBL] [Abstract][Full Text] [Related]
9. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer]. Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974 [TBL] [Abstract][Full Text] [Related]
10. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
11. Development of optimized cryptic peptides for immunotherapy. Menez-Jamet J; Kosmatopoulos K IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883 [TBL] [Abstract][Full Text] [Related]
12. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913 [TBL] [Abstract][Full Text] [Related]
14. Innovative cancer vaccine strategies based on the identification of tumour-associated antigens. Ying H; Zeng G; Black KL BioDrugs; 2001; 15(12):819-31. PubMed ID: 11784213 [TBL] [Abstract][Full Text] [Related]
15. Genetically modified tumour vaccines--where we are today. Nawrocki S; Mackiewicz A Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588 [TBL] [Abstract][Full Text] [Related]
16. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919 [TBL] [Abstract][Full Text] [Related]